| Literature DB >> 25496816 |
Hiroyuki Nakanishi1, Masayuki Kurosaki1, Kaoru Tsuchiya1, Natsuko Nakakuki1, Hitomi Takada1, Shuya Matsuda1, Kouichi Gondo1, Yu Asano1, Nobuhiro Hattori1, Nobuharu Tamaki1, Shoko Suzuki1, Yutaka Yasui1, Takanori Hosokawa1, Jun Itakura1, Yuka Takahashi1, Namiki Izumi2.
Abstract
We performed a prospective study to evaluate the ability of L-carnitine, which is involved in the β-oxidation of fatty acids, to reduce muscle cramps in patients with cirrhosis. Consecutive patients with cirrhosis and muscle cramps were given L-carnitine 300 mg, 3 times/day (900 mg/day, n = 19) or 4 times/day (1200 mg/day, n = 23) for 8 weeks. The frequency of muscle cramps was assessed by questionnaires, and the degree of muscle cramping was assessed by using the visual analogue scale (VAS). Muscle cramping was reduced in 88.1% of all subjects at the end of the 8-week study period and disappeared for 28.6% of patients. Overall VAS scores decreased significantly from 69.9 ± 22.5 at baseline to 26.2 ± 29.1 after 8 weeks (P < .0001). The dose of L-carnitine was significantly associated with percentages of patients with reduced muscle cramps after 8 weeks (43.5% in the 1200 mg/day group vs 10.5% in the 900 mg/day group, P = .037) and VAS scores at 8 weeks (9.9 ± 13.5 in the 1200 mg/day group vs 39.6 ± 31.9 in the 900 mg/day group, P = .003). No adverse events were reported. Therefore, L-carnitine appears to be safe and effective for reducing liver cramps in patients with cirrhosis.Entities:
Keywords: Clinical Trial; Fatty Acid; Lipid Metabolism; Liver Fibrosis
Mesh:
Substances:
Year: 2014 PMID: 25496816 DOI: 10.1016/j.cgh.2014.12.005
Source DB: PubMed Journal: Clin Gastroenterol Hepatol ISSN: 1542-3565 Impact factor: 11.382